



**PROFICIENCY TESTING SERVICE
AMERICAN ASSOCIATION OF BIOANALYSTS**

205 West Levee St. ♦ Brownsville, TX 78520-5596
800-234-5315 ♦ 956-546-5315 ♦ Fax 956-542-4041

ANTIMICROBIAL SUSCEPTIBILITIES

PARTICIPANT STATISTICS

SECOND QUADRIMESTER 2011

ANTIMICROBIAL SUSCEPTIBILITIES vs. *Proteus mirabilis*

Antimicrobial Agent	*CLSI Group	Resistant					Intermediate					Susceptible					
		Code	A-D	Bkpt	MIC	Total	Code	A-D	Bkpt	MIC	Total	Code	A-D	Bkpt	MIC	Total	
Amikacin	B	102			1	1	202					302	25	25	70	132	
Amoxicillin/clavulanate	B	104			2	2	204					304	79	32	57	175	
Ampicillin	A	105		1	4	5	205				1	1	305	132	47	95	290
Ampicillin/sulbactam	B	107			2	2	207				1	1	307	4	28	60	99
Aztreonam	C	110		5	2	7	210					310	2	23	29	58	
Carbenicillin	O	111					211					311	33		2	36	
Cefazolin	A	116			1	1	216					316	25	45	95	177	
Cefotaxime	B	125					225					325	12	29	39	87	
Cefotetan	B	126					226					326	6	12	13	31	
Cefoxitin	B	128					228					328	20	24	37	85	
Ceftazidime	C	129			1	1	229					329	14	27	59	106	
Ceftriaxone	B	132					232					332	49	37	77	171	
Cefuroxime/Cef Axetil	B	134			1	1	234					334	23	13	16	57	
Cephalothin	U	137				1	237					337	99	27	23	156	
Ciprofloxacin	B	141	1	1	1	3	241				1	341	132	40	105	292	
Gatifloxacin	O	145					245					345		1	12	15	
Gentamicin	A	153			1	1	253	1			1	2	353	109	43	96	263
Imipenem	B	155			2	2	255				1	1	355	14	36	41	99
Levofloxacin	B	154					254					354	59	40	85	195	
Meropenem	B	163			1	1	263					363		8	21	30	
Nalidixic acid	O	167					267					367	10		3	13	
Nitrofurantoin	C	171	137	44	80	274	271				3	3	371	1			1
Norfloxacin	C	173		1		1	273					373	37	7	6	53	
Ofloxacin	C	174					274					374	10		2	13	
Piperacillin	B	179					279					379	12	13	24	55	
Piperacillin/Tazobactam	B	181			1	1	281				1	1	381	9	26	44	88
Tetracycline	C	189	89	33	44	178	289					389					
Ticarcillin	O	191					291					391	4		4	10	
Ticarcillin/clavulanate	B	192			1	1	292				1	1	392	4	12	26	44
Tobramycin	A	194					294				2	2	394	24	27	65	121
Trimethoprim	C	195					295					395	9		4	15	
Trimethoprim/sulfamethoxazole	B	197	1			1	297					397	137	43	94	291	

Correct responses for Antimicrobial Susceptibilities are defined as those reflecting agreement among 90% or more of all participants. Unacceptable responses are demonstrated by shading.

* CLSI suggested grouping of U. S. FDA-Approved Antimicrobial Agents that should be considered for routine testing and reporting on this organism.

- | | |
|--|--|
| Group A - Primary Test & Report | Group C - Supplemental, Report Selectively |
| Group B - Primary Test, Report Selectively | Group U - Supplemental, For Urine Only |
| Group O - Other, Not Routine, Clinical Indication for Organism Group | |

Per CMS requirements, participants will be flagged for inappropriate selection of Antimicrobial Agents as listed in CLSI (NCCLS) guidelines M2-A8 and M7-A6. Scoring will be affected by selection of an incorrect Antimicrobial and will be counted as incorrect whether or not the organism's antimicrobial susceptibility was determined correctly. Antimicrobial agents that are not listed in the CLSI guidelines as appropriate for the identified organism that were reported are:

- | | | |
|--------------|----------------|-------------|
| Azithromycin | Clarithromycin | Teicoplanin |
| Ceforanide | Colistin | Vancomycin |
| | Moxifloxacin | |